Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Llibre JM, et al. Among authors: blair ea. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310899 Clinical Trial.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Aboud M, et al. Among authors: blair ea. Lancet HIV. 2019 Sep;6(9):e576-e587. doi: 10.1016/S2352-3018(19)30149-3. Epub 2019 Jul 12. Lancet HIV. 2019. PMID: 31307948 Clinical Trial.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Plerixafor for the Treatment of WHIM Syndrome.
McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. McDermott DH, et al. Among authors: blair ea. N Engl J Med. 2019 Jan 10;380(2):163-170. doi: 10.1056/NEJMoa1808575. N Engl J Med. 2019. PMID: 30625055 Free PMC article.
A herpetic hickey.
del Rosario NC, Blair E, Rickman L. del Rosario NC, et al. N Engl J Med. 1987 Jul 2;317(1):54-5. doi: 10.1056/nejm198707023170115. N Engl J Med. 1987. PMID: 3587315 No abstract available.
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits.
Hara JH, Gutiontov SI, Uddin S, Rosenberg AJ, Pearson AT, Gooi Z, Blair EA, Agrawal N, Vokes EE, Ginat DT, Haraf DJ, Juloori A. Hara JH, et al. Among authors: blair ea. Cureus. 2022 Jul 31;14(7):e27521. doi: 10.7759/cureus.27521. eCollection 2022 Jul. Cureus. 2022. PMID: 36060366 Free PMC article.
66 results